. . . . . . . . . "Ein Untereinheitenimpfstoff (englisch subunit vaccine) ist ein Totimpfstoff, der aus einem Teil eines Pathogens besteht."@de . . . . "Een subeenheid-prote\u00EFnevaccin of subunit-vaccin is een inert vaccin dat geen intacte, volledige viruspartikels bevat maar \u00E9\u00E9n of meerdere of semi-gezuiverde eiwitten waarbij andere viruscomponenten zijn verwijderd. Vaak worden slechts enkele zorgvuldig geselecteerde eiwitten van het virus of de bacterie gebruikt als antigenen voor de samenstelling van het vaccin. Als vaccinatie tegen coronavirussen produceert men bijvoorbeeld de spike-eiwitten van het virusomhulsel."@nl . . "Vacc\u00ED de subunitats"@ca . . . . . . . "Een subeenheid-prote\u00EFnevaccin of subunit-vaccin is een inert vaccin dat geen intacte, volledige viruspartikels bevat maar \u00E9\u00E9n of meerdere of semi-gezuiverde eiwitten waarbij andere viruscomponenten zijn verwijderd. Vaak worden slechts enkele zorgvuldig geselecteerde eiwitten van het virus of de bacterie gebruikt als antigenen voor de samenstelling van het vaccin. Als vaccinatie tegen coronavirussen produceert men bijvoorbeeld de spike-eiwitten van het virusomhulsel. Bij de subunit-vaccins worden de micro-organismen eerst in celculturen gekweekt en daarna worden de antigenen (eiwitten) via chemische weg losgeweekt."@nl . . . . . . . . "\u30B5\u30D6\u30E6\u30CB\u30C3\u30C8\u30EF\u30AF\u30C1\u30F3\uFF08\u82F1: subunit vaccine\uFF09\u3068\u306F\u3001\u75C5\u539F\u4F53\u7C92\u5B50\u3092\u5168\u4F53\u7684\u307E\u305F\u306F\u305D\u306E\u4ED6\u306E\u65B9\u6CD5\u3067\u5C0E\u5165\u3059\u308B\u3053\u3068\u306A\u304F\u3001\u514D\u75AB\u7CFB\u306B1\u3064\u4EE5\u4E0A\u306E\u6297\u539F\u3092\u63D0\u793A\u3059\u308B\u30EF\u30AF\u30C1\u30F3\u3067\u3042\u308B\u3002\u6297\u539F\u306F\u3069\u306E\u3088\u3046\u306A\u5206\u5B50\u3067\u3042\u3063\u3066\u3082\u3088\u304F\u3001\u30BF\u30F3\u30D1\u30AF\u8CEA\u306E\u30B5\u30D6\u30E6\u30CB\u30C3\u30C8\u3067\u3042\u308B\u5FC5\u8981\u306F\u306A\u3044\u3002\u300C\u30B5\u30D6\u30E6\u30CB\u30C3\u30C8\u300D\u3068\u3044\u3046\u8A00\u8449\u306F\u3001\u5358\u306B\u6297\u539F\u304C\u75C5\u539F\u4F53\u306E\u65AD\u7247\u3067\u3042\u308B\u3053\u3068\u3092\u610F\u5473\u3059\u308B\u3002\u4E0D\u6D3B\u5316\u30EF\u30AF\u30C1\u30F3\u3068\u540C\u69D8\u306B\u3001\u30EF\u30AF\u30C1\u30F3\u306F\u5B8C\u5168\u306B\u300C\u6B7B\u6EC5\u300D\u3057\u3066\u3044\u308B\u305F\u3081\u3001\u30EA\u30B9\u30AF\u304C\u4F4E\u304F\u306A\u3063\u3066\u3044\u308B\u3002"@ja . . "21861922"^^ . . "\u4E9E\u55AE\u4F4D\u75AB\u82D7"@zh . . . "Vaccin \u00E0 sous-unit\u00E9s"@fr . . . . . "Las vacunas de subunidades son vacunas de nueva generaci\u00F3n dise\u00F1adas a partir de componentes de virus o bacterias, las cuales desencadenan la respuesta inmunitaria al individuo al que se le administra. Es un m\u00E9todo sencillo y pr\u00E1ctico para inmunizar a los individuos sin peligro tanto de padecer la enfermedad como de tener efectos adversos debido a la presencia s\u00F3lo de los ant\u00EDgenos espec\u00EDficos, rechazando as\u00ED los otros componentes que pueden ser pat\u00F3genos. Se suelen utilizar para aquellos agentes infecciosos que no se pueden mantener en cultivos como el virus de la influenza o de la hepatitis B.\u200B"@es . "\u30B5\u30D6\u30E6\u30CB\u30C3\u30C8\u30EF\u30AF\u30C1\u30F3\uFF08\u82F1: subunit vaccine\uFF09\u3068\u306F\u3001\u75C5\u539F\u4F53\u7C92\u5B50\u3092\u5168\u4F53\u7684\u307E\u305F\u306F\u305D\u306E\u4ED6\u306E\u65B9\u6CD5\u3067\u5C0E\u5165\u3059\u308B\u3053\u3068\u306A\u304F\u3001\u514D\u75AB\u7CFB\u306B1\u3064\u4EE5\u4E0A\u306E\u6297\u539F\u3092\u63D0\u793A\u3059\u308B\u30EF\u30AF\u30C1\u30F3\u3067\u3042\u308B\u3002\u6297\u539F\u306F\u3069\u306E\u3088\u3046\u306A\u5206\u5B50\u3067\u3042\u3063\u3066\u3082\u3088\u304F\u3001\u30BF\u30F3\u30D1\u30AF\u8CEA\u306E\u30B5\u30D6\u30E6\u30CB\u30C3\u30C8\u3067\u3042\u308B\u5FC5\u8981\u306F\u306A\u3044\u3002\u300C\u30B5\u30D6\u30E6\u30CB\u30C3\u30C8\u300D\u3068\u3044\u3046\u8A00\u8449\u306F\u3001\u5358\u306B\u6297\u539F\u304C\u75C5\u539F\u4F53\u306E\u65AD\u7247\u3067\u3042\u308B\u3053\u3068\u3092\u610F\u5473\u3059\u308B\u3002\u4E0D\u6D3B\u5316\u30EF\u30AF\u30C1\u30F3\u3068\u540C\u69D8\u306B\u3001\u30EF\u30AF\u30C1\u30F3\u306F\u5B8C\u5168\u306B\u300C\u6B7B\u6EC5\u300D\u3057\u3066\u3044\u308B\u305F\u3081\u3001\u30EA\u30B9\u30AF\u304C\u4F4E\u304F\u306A\u3063\u3066\u3044\u308B\u3002"@ja . . . "\u0644\u0642\u0627\u062D \u0627\u0644\u0648\u062D\u064A\u062F\u0627\u062A"@ar . . . . . . . . "Las vacunas de subunidades son vacunas de nueva generaci\u00F3n dise\u00F1adas a partir de componentes de virus o bacterias, las cuales desencadenan la respuesta inmunitaria al individuo al que se le administra. Es un m\u00E9todo sencillo y pr\u00E1ctico para inmunizar a los individuos sin peligro tanto de padecer la enfermedad como de tener efectos adversos debido a la presencia s\u00F3lo de los ant\u00EDgenos espec\u00EDficos, rechazando as\u00ED los otros componentes que pueden ser pat\u00F3genos. Se suelen utilizar para aquellos agentes infecciosos que no se pueden mantener en cultivos como el virus de la influenza o de la hepatitis B.\u200B"@es . . . . "A subunit vaccine is a vaccine that contains purified parts of the pathogen that are antigenic, or necessary to elicit a protective immune response.A \"subunit\" vaccine doesn't contain the whole pathogen, unlike live attenuated or inactivated vaccine, but contains only the antigenic parts such as proteins, polysaccharides or peptides.Because the vaccine doesn't contain \"live\" components of the pathogen, there is no risk of introducing the disease, and is safer and more stable than vaccine containing whole pathogens.Other advantages include being well-established technology and being suitable for immunocompromised individuals.Disadvantages include being relatively complex to manufacture compared to some vaccines, possibly requiring adjuvants and booster shots, and requiring time to examine which antigenic combinations may work best."@en . "Subunit vaccine"@en . . . . "Un vaccin \u00E0 sous-unit\u00E9s ou vaccin sous-unitaire est un vaccin qui contient des parties purifi\u00E9es d'agents pathog\u00E8nes qui sont antig\u00E9niques ou n\u00E9cessaires pour induire une r\u00E9ponse immunitaire protectrice.Au contraire d'un vaccin \u00E0 virus att\u00E9nu\u00E9 ou \u00E0 virus inactiv\u00E9, il ne contient que les parties antig\u00E9niques telles que des sous-unit\u00E9s prot\u00E9iquess, des polysaccharides ou des peptides.Puisqu'il ne contient aucune partie \u00AB vivante \u00BB de l'agent pathog\u00E8ne, il n'y a aucun risque qu'il introduise la maladie, il est plus s\u00E9curitaire et plus stable stable qu'un vaccin qui contient le pathog\u00E8ne complet.Il pr\u00E9sente deux autres avantages : la technologie de production est bien document\u00E9e au XXIe si\u00E8cle et il est efficace pour les personnes immunosupprim\u00E9e.Sa cr\u00E9ation, sa production et son inoculation pr\u00E9sente des d\u00E9savantages : la recherche de la bonne combinaison de fragments antig\u00E9niques exige du temps, il est plus complexe \u00E0 fabriquer que certains vaccins \u00E0 ARN, il peut exiger des adjuvants immunologiques pour augmenter son efficacit\u00E9 et des doses de rappel peuvent \u00EAtre n\u00E9cessaires pour la m\u00EAme raison."@fr . "Ein Untereinheitenimpfstoff (englisch subunit vaccine) ist ein Totimpfstoff, der aus einem Teil eines Pathogens besteht."@de . "Una vacuna de subunitats o vacc\u00ED de subunitats \u00E9s una vacuna de nova generaci\u00F3 dissenyada a partir de components de virus o bacteris, els quals desencadenen la resposta immunit\u00E0ria a l'individu a qui se li administra. \u00C9s un m\u00E8tode senzill i pr\u00E0ctic per immunitzar als individus sense perill tant de patir la malaltia com de tenir efectes adversos degut a la pres\u00E8ncia nom\u00E9s dels ant\u00EDgens espec\u00EDfics, rebutjant aix\u00ED els altres components que poden ser pat\u00F2gens.Se solen utilitzar per a aquells agents infecciosos que no es poden mantenir en cultius com el virus de la influen\u00E7a o de l'hepatitis B."@ca . "\u0644\u0642\u0627\u062D \u0627\u0644\u0648\u064F\u062D\u064E\u064A\u0652\u062F\u0627\u062A \u0623\u0648 \u0644\u0642\u0627\u062D \u0627\u0644\u0648\u062D\u062F\u0627\u062A \u0627\u0644\u0641\u0631\u0639\u064A\u0629 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Subunit vaccine)\u200F\u061B \u0647\u0648 \u0644\u0642\u0627\u062D \u064A\u0642\u062F\u0645 \u0648\u0627\u062D\u062F\u064B\u0627 \u0623\u0648 \u0623\u0643\u062B\u0631 \u0645\u0646 \u0627\u0644\u0645\u0633\u062A\u0636\u062F\u0627\u062A \u0644\u062C\u0647\u0627\u0632 \u0627\u0644\u0645\u0646\u0627\u0639\u0629 \u062F\u0648\u0646 \u0625\u062F\u062E\u0627\u0644 \u062C\u0632\u064A\u0626\u0627\u062A \u0645\u0633\u0628\u0628\u0629 \u0644\u0644\u0623\u0645\u0631\u0627\u0636\u060C \u0643\u0627\u0645\u0644\u0629 \u0623\u0648 \u063A\u064A\u0631 \u0630\u0644\u0643. \u064A\u0639\u0646\u064A \u0645\u0635\u0637\u0644\u062D \u00AB\u0627\u0644\u0648\u062D\u062F\u0629 \u0627\u0644\u0641\u0631\u0639\u064A\u0629\u00BB \u0628\u0628\u0633\u0627\u0637\u0629 \u0623\u0646 \u0627\u0644\u0645\u0633\u062A\u0636\u062F \u0647\u0648 \u062C\u0632\u0621 \u0645\u0646 \u0627\u0644\u0639\u0627\u0645\u0644 \u0627\u0644\u0645\u0645\u0631\u0636\u060C \u0648\u064A\u0645\u0643\u0646 \u0623\u0646 \u062A\u0643\u0648\u0646 \u0627\u0644\u0645\u0633\u062A\u0636\u062F\u0627\u062A \u0627\u0644\u0645\u0639\u0646\u064A\u0629 \u0623\u064A \u062C\u0632\u064A\u0621\u060C \u0645\u062B\u0644 \u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646\u0627\u062A \u0623\u0648 \u0627\u0644\u0628\u0628\u062A\u064A\u062F\u0627\u062A \u0623\u0648 \u0627\u0644\u0633\u0643\u0631\u064A\u0627\u062A \u0627\u0644\u0645\u062A\u0639\u062F\u062F\u0629. \u062A\u0639\u062F \u0644\u0642\u0627\u062D\u0627\u062A \u0627\u0644\u0648\u062D\u064A\u062F\u0627\u062A\u060C \u0645\u062B\u0644\u0647\u0627 \u0645\u062B\u0644 \u0627\u0644\u0644\u0642\u0627\u062D\u0627\u062A \u0627\u0644\u0645\u0639\u0637\u0644\u0629 \u0644\u0642\u0627\u062D\u0627\u062A \u00AB\u0645\u064A\u062A\u0629\u00BB \u0628\u0627\u0644\u0643\u0627\u0645\u0644\u060C \u0648\u0647\u064A \u0628\u0630\u0644\u0643 \u0630\u0627\u062A \u062E\u0637\u0648\u0631\u0629 \u0642\u0644\u064A\u0644\u0629."@ar . . . "Una vacuna de subunitats o vacc\u00ED de subunitats \u00E9s una vacuna de nova generaci\u00F3 dissenyada a partir de components de virus o bacteris, els quals desencadenen la resposta immunit\u00E0ria a l'individu a qui se li administra. \u00C9s un m\u00E8tode senzill i pr\u00E0ctic per immunitzar als individus sense perill tant de patir la malaltia com de tenir efectes adversos degut a la pres\u00E8ncia nom\u00E9s dels ant\u00EDgens espec\u00EDfics, rebutjant aix\u00ED els altres components que poden ser pat\u00F2gens.Se solen utilitzar per a aquells agents infecciosos que no es poden mantenir en cultius com el virus de la influen\u00E7a o de l'hepatitis B."@ca . "1103294322"^^ . . . . "Podjednotkov\u00E1 vakc\u00EDna je vakc\u00EDna, kter\u00E1 obsahuje o\u010Di\u0161t\u011Bn\u00E9 \u010D\u00E1sti patogenu, kter\u00E9 jsou antigenn\u00ED nebo nezbytn\u00E9 k vyvol\u00E1n\u00ED ochrann\u00E9 imunitn\u00ED reakce. Neobsahuje cel\u00FD patogen, na rozd\u00EDl od \u017Eiv\u00E9 oslaben\u00E9 nebo inaktivovan\u00E9 vakc\u00EDny, ale obsahuje pouze antigenn\u00ED \u010D\u00E1stice, jako jsou proteiny, polysacharidy nebo peptidy. Vzhledem k tomu, \u017Ee vakc\u00EDna neobsahuje \u017Eiv\u00E9 slo\u017Eky patogenu, neexistuje \u017E\u00E1dn\u00E9 riziko zavle\u010Den\u00ED onemocn\u011Bn\u00ED; podjednotkov\u00E1 vakc\u00EDna je tedy bezpe\u010Dn\u011Bj\u0161\u00ED a stabiln\u011Bj\u0161\u00ED ne\u017E vakc\u00EDna obsahuj\u00EDc\u00ED cel\u00E9 patogeny. Mezi dal\u0161\u00ED v\u00FDhody pat\u0159\u00ED dob\u0159e zaveden\u00E1 technologie a vhodnost pro lidi s imunodeficienc\u00ED. Nev\u00FDhody zahrnuj\u00ED relativn\u011B slo\u017Eitou v\u00FDrobu ve srovn\u00E1n\u00ED s v\u00FDrobou n\u011Bkter\u00FDch jin\u00FDch vakc\u00EDn (jako je RNA vakc\u00EDna), p\u0159\u00EDpadn\u011B pot\u0159eba adjuvans a posilovac\u00ED injekce a pot\u0159eba \u010Dasu na prozkoum\u00E1n\u00ED, kter\u00E9 antigenn\u00ED kombinace mohou fungovat nejl\u00E9pe."@cs . . "\u0644\u0642\u0627\u062D \u0627\u0644\u0648\u064F\u062D\u064E\u064A\u0652\u062F\u0627\u062A \u0623\u0648 \u0644\u0642\u0627\u062D \u0627\u0644\u0648\u062D\u062F\u0627\u062A \u0627\u0644\u0641\u0631\u0639\u064A\u0629 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Subunit vaccine)\u200F\u061B \u0647\u0648 \u0644\u0642\u0627\u062D \u064A\u0642\u062F\u0645 \u0648\u0627\u062D\u062F\u064B\u0627 \u0623\u0648 \u0623\u0643\u062B\u0631 \u0645\u0646 \u0627\u0644\u0645\u0633\u062A\u0636\u062F\u0627\u062A \u0644\u062C\u0647\u0627\u0632 \u0627\u0644\u0645\u0646\u0627\u0639\u0629 \u062F\u0648\u0646 \u0625\u062F\u062E\u0627\u0644 \u062C\u0632\u064A\u0626\u0627\u062A \u0645\u0633\u0628\u0628\u0629 \u0644\u0644\u0623\u0645\u0631\u0627\u0636\u060C \u0643\u0627\u0645\u0644\u0629 \u0623\u0648 \u063A\u064A\u0631 \u0630\u0644\u0643. \u064A\u0639\u0646\u064A \u0645\u0635\u0637\u0644\u062D \u00AB\u0627\u0644\u0648\u062D\u062F\u0629 \u0627\u0644\u0641\u0631\u0639\u064A\u0629\u00BB \u0628\u0628\u0633\u0627\u0637\u0629 \u0623\u0646 \u0627\u0644\u0645\u0633\u062A\u0636\u062F \u0647\u0648 \u062C\u0632\u0621 \u0645\u0646 \u0627\u0644\u0639\u0627\u0645\u0644 \u0627\u0644\u0645\u0645\u0631\u0636\u060C \u0648\u064A\u0645\u0643\u0646 \u0623\u0646 \u062A\u0643\u0648\u0646 \u0627\u0644\u0645\u0633\u062A\u0636\u062F\u0627\u062A \u0627\u0644\u0645\u0639\u0646\u064A\u0629 \u0623\u064A \u062C\u0632\u064A\u0621\u060C \u0645\u062B\u0644 \u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646\u0627\u062A \u0623\u0648 \u0627\u0644\u0628\u0628\u062A\u064A\u062F\u0627\u062A \u0623\u0648 \u0627\u0644\u0633\u0643\u0631\u064A\u0627\u062A \u0627\u0644\u0645\u062A\u0639\u062F\u062F\u0629. \u062A\u0639\u062F \u0644\u0642\u0627\u062D\u0627\u062A \u0627\u0644\u0648\u062D\u064A\u062F\u0627\u062A\u060C \u0645\u062B\u0644\u0647\u0627 \u0645\u062B\u0644 \u0627\u0644\u0644\u0642\u0627\u062D\u0627\u062A \u0627\u0644\u0645\u0639\u0637\u0644\u0629 \u0644\u0642\u0627\u062D\u0627\u062A \u00AB\u0645\u064A\u062A\u0629\u00BB \u0628\u0627\u0644\u0643\u0627\u0645\u0644\u060C \u0648\u0647\u064A \u0628\u0630\u0644\u0643 \u0630\u0627\u062A \u062E\u0637\u0648\u0631\u0629 \u0642\u0644\u064A\u0644\u0629."@ar . . . . . "\uC18C\uB2E8\uC704 \uBC31\uC2E0"@ko . . "\u30B5\u30D6\u30E6\u30CB\u30C3\u30C8\u30EF\u30AF\u30C1\u30F3"@ja . . . . . "\uC18C\uB2E8\uC704 \uBC31\uC2E0(subunit vaccine), \uB610\uB294 \uC11C\uBE0C\uC720\uB2DB \uBC31\uC2E0\uC740 \uD56D\uC6D0\uC131\uC774\uAC70\uB098 \uBC29\uC5B4\uB97C \uC704\uD55C \uBA74\uC5ED \uBC18\uC751\uC744 \uC720\uB3C4\uD558\uB294 \uB370 \uD544\uC694\uD55C \uBCD1\uC6D0\uCCB4\uC758 \uC815\uC81C\uB41C \uBD80\uBD84\uC744 \uD3EC\uD568\uD558\uB294 \uBC31\uC2E0\uC774\uB2E4. '\uC18C\uB2E8\uC704' \uBC31\uC2E0\uC740 \uC57D\uB3C5\uD654 \uBC31\uC2E0\uC774\uB098 \uBE44\uD65C\uC131\uD654 \uBC31\uC2E0\uACFC \uB2EC\uB9AC \uBCD1\uC6D0\uCCB4 \uC804\uCCB4\uB97C \uD3EC\uD568\uD558\uC9C0 \uC54A\uACE0, \uB2E8\uBC31\uC9C8, \uB2E4\uB2F9\uB958, \uD3A9\uD0C0\uC774\uB4DC\uC640 \uAC19\uC740 \uD56D\uC6D0 \uBD80\uBD84\uB9CC \uD3EC\uD568\uD55C\uB2E4. \uBCD1\uC6D0\uCCB4\uC758 '\uC0B4\uC544\uC788\uB294' \uC131\uBD84\uC744 \uD3EC\uD568\uD558\uC9C0 \uC54A\uAE30 \uB54C\uBB38\uC5D0 \uC9C8\uBCD1\uC744 \uC77C\uC73C\uD0AC \uC704\uD5D8\uC774 \uC5C6\uC73C\uBA70 \uC804\uCCB4 \uBCD1\uC6D0\uCCB4\uB97C \uD3EC\uD568\uD558\uB294 \uBC31\uC2E0\uBCF4\uB2E4 \uB354 \uC548\uC804\uD558\uACE0 \uC548\uC815\uC801\uC774\uB2E4. \uB2E4\uB978 \uC7A5\uC810\uC740 \uAE30\uC220\uC774 \uC798 \uBC1C\uC804\uD574 \uC788\uC73C\uBA70, \uBA74\uC5ED\uC774 \uC190\uC0C1\uB41C \uC0AC\uB78C\uB4E4\uC5D0\uAC8C \uC801\uD569\uD558\uB2E4\uB294 \uAC83\uC774\uB2E4. \uB2E8\uC810\uC73C\uB85C\uB294 RNA \uBC31\uC2E0\uACFC \uAC19\uC740 \uC77C\uBD80 \uB2E4\uB978 \uBC31\uC2E0 \uC885\uB958\uC5D0 \uBE44\uD574 \uC81C\uC870\uAC00 \uBE44\uAD50\uC801 \uBCF5\uC7A1\uD558\uACE0, \uB098 \uCD94\uAC00 \uC811\uC885\uC774 \uD544\uC694\uD560 \uC218 \uC788\uC73C\uBA70, \uC5B4\uB5A4 \uD56D\uC6D0 \uC870\uD569\uC774 \uAC00\uC7A5 \uD6A8\uACFC\uAC00 \uC788\uC744\uC9C0 \uC870\uC0AC\uD558\uB294 \uB370 \uC2DC\uAC04\uC774 \uD544\uC694\uD558\uB2E4\uB294 \uC810 \uB4F1\uC774 \uC788\uB2E4."@ko . . . . . . . . "Untereinheitenimpfstoff"@de . . "Subunit-vaccin"@nl . "15079"^^ . . . "Vacuna de subunidades"@es . "\uC18C\uB2E8\uC704 \uBC31\uC2E0(subunit vaccine), \uB610\uB294 \uC11C\uBE0C\uC720\uB2DB \uBC31\uC2E0\uC740 \uD56D\uC6D0\uC131\uC774\uAC70\uB098 \uBC29\uC5B4\uB97C \uC704\uD55C \uBA74\uC5ED \uBC18\uC751\uC744 \uC720\uB3C4\uD558\uB294 \uB370 \uD544\uC694\uD55C \uBCD1\uC6D0\uCCB4\uC758 \uC815\uC81C\uB41C \uBD80\uBD84\uC744 \uD3EC\uD568\uD558\uB294 \uBC31\uC2E0\uC774\uB2E4. '\uC18C\uB2E8\uC704' \uBC31\uC2E0\uC740 \uC57D\uB3C5\uD654 \uBC31\uC2E0\uC774\uB098 \uBE44\uD65C\uC131\uD654 \uBC31\uC2E0\uACFC \uB2EC\uB9AC \uBCD1\uC6D0\uCCB4 \uC804\uCCB4\uB97C \uD3EC\uD568\uD558\uC9C0 \uC54A\uACE0, \uB2E8\uBC31\uC9C8, \uB2E4\uB2F9\uB958, \uD3A9\uD0C0\uC774\uB4DC\uC640 \uAC19\uC740 \uD56D\uC6D0 \uBD80\uBD84\uB9CC \uD3EC\uD568\uD55C\uB2E4. \uBCD1\uC6D0\uCCB4\uC758 '\uC0B4\uC544\uC788\uB294' \uC131\uBD84\uC744 \uD3EC\uD568\uD558\uC9C0 \uC54A\uAE30 \uB54C\uBB38\uC5D0 \uC9C8\uBCD1\uC744 \uC77C\uC73C\uD0AC \uC704\uD5D8\uC774 \uC5C6\uC73C\uBA70 \uC804\uCCB4 \uBCD1\uC6D0\uCCB4\uB97C \uD3EC\uD568\uD558\uB294 \uBC31\uC2E0\uBCF4\uB2E4 \uB354 \uC548\uC804\uD558\uACE0 \uC548\uC815\uC801\uC774\uB2E4. \uB2E4\uB978 \uC7A5\uC810\uC740 \uAE30\uC220\uC774 \uC798 \uBC1C\uC804\uD574 \uC788\uC73C\uBA70, \uBA74\uC5ED\uC774 \uC190\uC0C1\uB41C \uC0AC\uB78C\uB4E4\uC5D0\uAC8C \uC801\uD569\uD558\uB2E4\uB294 \uAC83\uC774\uB2E4. \uB2E8\uC810\uC73C\uB85C\uB294 RNA \uBC31\uC2E0\uACFC \uAC19\uC740 \uC77C\uBD80 \uB2E4\uB978 \uBC31\uC2E0 \uC885\uB958\uC5D0 \uBE44\uD574 \uC81C\uC870\uAC00 \uBE44\uAD50\uC801 \uBCF5\uC7A1\uD558\uACE0, \uB098 \uCD94\uAC00 \uC811\uC885\uC774 \uD544\uC694\uD560 \uC218 \uC788\uC73C\uBA70, \uC5B4\uB5A4 \uD56D\uC6D0 \uC870\uD569\uC774 \uAC00\uC7A5 \uD6A8\uACFC\uAC00 \uC788\uC744\uC9C0 \uC870\uC0AC\uD558\uB294 \uB370 \uC2DC\uAC04\uC774 \uD544\uC694\uD558\uB2E4\uB294 \uC810 \uB4F1\uC774 \uC788\uB2E4."@ko . . . "Un vaccin \u00E0 sous-unit\u00E9s ou vaccin sous-unitaire est un vaccin qui contient des parties purifi\u00E9es d'agents pathog\u00E8nes qui sont antig\u00E9niques ou n\u00E9cessaires pour induire une r\u00E9ponse immunitaire protectrice.Au contraire d'un vaccin \u00E0 virus att\u00E9nu\u00E9 ou \u00E0 virus inactiv\u00E9, il ne contient que les parties antig\u00E9niques telles que des sous-unit\u00E9s prot\u00E9iquess, des polysaccharides ou des peptides.Puisqu'il ne contient aucune partie \u00AB vivante \u00BB de l'agent pathog\u00E8ne, il n'y a aucun risque qu'il introduise la maladie, il est plus s\u00E9curitaire et plus stable stable qu'un vaccin qui contient le pathog\u00E8ne complet.Il pr\u00E9sente deux autres avantages : la technologie de production est bien document\u00E9e au XXIe si\u00E8cle et il est efficace pour les personnes immunosupprim\u00E9e.Sa cr\u00E9ation, sa production et son inoculation p"@fr . "A subunit vaccine is a vaccine that contains purified parts of the pathogen that are antigenic, or necessary to elicit a protective immune response.A \"subunit\" vaccine doesn't contain the whole pathogen, unlike live attenuated or inactivated vaccine, but contains only the antigenic parts such as proteins, polysaccharides or peptides.Because the vaccine doesn't contain \"live\" components of the pathogen, there is no risk of introducing the disease, and is safer and more stable than vaccine containing whole pathogens.Other advantages include being well-established technology and being suitable for immunocompromised individuals.Disadvantages include being relatively complex to manufacture compared to some vaccines, possibly requiring adjuvants and booster shots, and requiring time to examine w"@en . . . "Podjednotkov\u00E1 vakc\u00EDna"@cs . . "\u6B21\u55AE\u5143\u75AB\u82D7\uFF08\u82F1\u8A9E\uFF1ASubunit vaccine\uFF09\uFF0C\u53C8\u7A31\u4E9E\u55AE\u4F4D\u75AB\u82D7\u3001\u6B21\u5355\u4F4D\u75AB\u82D7\uFF0C\u70BA\u75AB\u82D7\u7684\u4E00\u7A2E\uFF0C\u6B21\u55AE\u5143\u75AB\u82D7\u53EA\u542B\u6709\u75C5\u539F\u9AD4\u4E2D\u5177\u6709\u6297\u539F\u6027\u7684\u90E8\u5206\uFF0C\u4E5F\u5C31\u662F\u53EF\u4EE5\u8A98\u767C\u514D\u75AB\u53CD\u61C9\u7684\u6297\u539F\u3002 \u4E0D\u50CF\u6E1B\u6BD2\u75AB\u82D7\u6216\u4E0D\u6D3B\u5316\u75AB\u82D7\u542B\u6709\u5B8C\u6574\u7684\u75C5\u539F\u9AD4\uFF0C\u6B21\u55AE\u5143\u75AB\u82D7\u53EA\u542B\u5177\u6709\u6297\u539F\u6027\u7684\u90E8\u5206\uFF0C\u4F8B\u5982\u86CB\u767D\u8CEA\u3001\u591A\u91A3\u6216\u80DC\u80BD\uFF0C\u56E0\u6B64\u4E0D\u6703\u6709\u5C0E\u81F4\u75BE\u75C5\u7684\u98A8\u96AA\uFF0C\u800C\u8F03\u542B\u6709\u5B8C\u6574\u75C5\u539F\u9AD4\u7684\u75AB\u82D7\u5B89\u5168\u4E14\u53EF\u9760\u3002\u5176\u5B83\u7684\u512A\u9EDE\u9084\u6709\u6B21\u55AE\u5143\u75AB\u82D7\u662F\u53D7\u5230\u5EE3\u6CDB\u8A8D\u53EF\u7684\u6280\u8853\uFF1B\u7F3A\u9EDE\u5247\u662F\u88FD\u9020\u904E\u7A0B\u8F03\u67D0\u4E9B\u75AB\u82D7\uFF08\u4F8B\u5982RNA\u75AB\u82D7\uFF09\u8907\u96DC\uFF0C\u800C\u4E14\u53EF\u80FD\u9700\u8981\u4F50\u5291\u548C\u8FFD\u52A0\u6CE8\u5C04\uFF0C\u4E5F\u9700\u8981\u6642\u9593\u53BB\u8A66\u9A57\u54EA\u7A2E\u6297\u539F\u80FD\u8A98\u767C\u6700\u597D\u7684\u514D\u75AB\u6548\u679C\u3002 \u8FD9\u7C7B\u75AB\u82D7\u4E2D\uFF0C\u6700\u5E38\u898B\u7684\u662F\u86CB\u767D\u8CEA\u4E9E\u55AE\u4F4D\u75AB\u82D7\uFF0C\u6B21\u5E38\u89C1\u7684\u662F\u7ED3\u5408(\u578B)\u75AB\u82D7\u3002"@zh . . . . . . . . "\u6B21\u55AE\u5143\u75AB\u82D7\uFF08\u82F1\u8A9E\uFF1ASubunit vaccine\uFF09\uFF0C\u53C8\u7A31\u4E9E\u55AE\u4F4D\u75AB\u82D7\u3001\u6B21\u5355\u4F4D\u75AB\u82D7\uFF0C\u70BA\u75AB\u82D7\u7684\u4E00\u7A2E\uFF0C\u6B21\u55AE\u5143\u75AB\u82D7\u53EA\u542B\u6709\u75C5\u539F\u9AD4\u4E2D\u5177\u6709\u6297\u539F\u6027\u7684\u90E8\u5206\uFF0C\u4E5F\u5C31\u662F\u53EF\u4EE5\u8A98\u767C\u514D\u75AB\u53CD\u61C9\u7684\u6297\u539F\u3002 \u4E0D\u50CF\u6E1B\u6BD2\u75AB\u82D7\u6216\u4E0D\u6D3B\u5316\u75AB\u82D7\u542B\u6709\u5B8C\u6574\u7684\u75C5\u539F\u9AD4\uFF0C\u6B21\u55AE\u5143\u75AB\u82D7\u53EA\u542B\u5177\u6709\u6297\u539F\u6027\u7684\u90E8\u5206\uFF0C\u4F8B\u5982\u86CB\u767D\u8CEA\u3001\u591A\u91A3\u6216\u80DC\u80BD\uFF0C\u56E0\u6B64\u4E0D\u6703\u6709\u5C0E\u81F4\u75BE\u75C5\u7684\u98A8\u96AA\uFF0C\u800C\u8F03\u542B\u6709\u5B8C\u6574\u75C5\u539F\u9AD4\u7684\u75AB\u82D7\u5B89\u5168\u4E14\u53EF\u9760\u3002\u5176\u5B83\u7684\u512A\u9EDE\u9084\u6709\u6B21\u55AE\u5143\u75AB\u82D7\u662F\u53D7\u5230\u5EE3\u6CDB\u8A8D\u53EF\u7684\u6280\u8853\uFF1B\u7F3A\u9EDE\u5247\u662F\u88FD\u9020\u904E\u7A0B\u8F03\u67D0\u4E9B\u75AB\u82D7\uFF08\u4F8B\u5982RNA\u75AB\u82D7\uFF09\u8907\u96DC\uFF0C\u800C\u4E14\u53EF\u80FD\u9700\u8981\u4F50\u5291\u548C\u8FFD\u52A0\u6CE8\u5C04\uFF0C\u4E5F\u9700\u8981\u6642\u9593\u53BB\u8A66\u9A57\u54EA\u7A2E\u6297\u539F\u80FD\u8A98\u767C\u6700\u597D\u7684\u514D\u75AB\u6548\u679C\u3002 \u8FD9\u7C7B\u75AB\u82D7\u4E2D\uFF0C\u6700\u5E38\u898B\u7684\u662F\u86CB\u767D\u8CEA\u4E9E\u55AE\u4F4D\u75AB\u82D7\uFF0C\u6B21\u5E38\u89C1\u7684\u662F\u7ED3\u5408(\u578B)\u75AB\u82D7\u3002"@zh . . . . "Podjednotkov\u00E1 vakc\u00EDna je vakc\u00EDna, kter\u00E1 obsahuje o\u010Di\u0161t\u011Bn\u00E9 \u010D\u00E1sti patogenu, kter\u00E9 jsou antigenn\u00ED nebo nezbytn\u00E9 k vyvol\u00E1n\u00ED ochrann\u00E9 imunitn\u00ED reakce. Neobsahuje cel\u00FD patogen, na rozd\u00EDl od \u017Eiv\u00E9 oslaben\u00E9 nebo inaktivovan\u00E9 vakc\u00EDny, ale obsahuje pouze antigenn\u00ED \u010D\u00E1stice, jako jsou proteiny, polysacharidy nebo peptidy. Vzhledem k tomu, \u017Ee vakc\u00EDna neobsahuje \u017Eiv\u00E9 slo\u017Eky patogenu, neexistuje \u017E\u00E1dn\u00E9 riziko zavle\u010Den\u00ED onemocn\u011Bn\u00ED; podjednotkov\u00E1 vakc\u00EDna je tedy bezpe\u010Dn\u011Bj\u0161\u00ED a stabiln\u011Bj\u0161\u00ED ne\u017E vakc\u00EDna obsahuj\u00EDc\u00ED cel\u00E9 patogeny. Mezi dal\u0161\u00ED v\u00FDhody pat\u0159\u00ED dob\u0159e zaveden\u00E1 technologie a vhodnost pro lidi s imunodeficienc\u00ED. Nev\u00FDhody zahrnuj\u00ED relativn\u011B slo\u017Eitou v\u00FDrobu ve srovn\u00E1n\u00ED s v\u00FDrobou n\u011Bkter\u00FDch jin\u00FDch vakc\u00EDn (jako je RNA vakc\u00EDna), p\u0159\u00EDpadn\u011B pot\u0159eba adjuvans a posilovac\u00ED injekce a pot\u0159eba \u010Dasu na prozkoum\u00E1n\u00ED, kter\u00E9 a"@cs . . .